Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04615923 · ClinicalTrials.gov registry record · Phase 2
HEALEY ALS Platform Trial - Regimen D Pridopidine
A Phase 2 study, sponsored by Merit E. Cudkowicz, MD.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT04615923: Completed Phase 2 study, sponsored by Merit E. Cudkowicz, MD.
NCT04615923 is a Phase 2 study that has completed, run by Merit E. Cudkowicz, MD. The registered enrollment target is 163 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04615923, a Phase 2 study, has completed, sponsored by Merit E. Cudkowicz, MD.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.
Primary Outcome
Change in disease severity over time as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R). Each type of function is scored from 4 (normal) to 0 (no ability), with a maximum total score of 48 and a minimum total score of 0. Patients with higher scores have more physical function.
Interventions
- DRUG Matching Placebo
- DRUG Pridopidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2020-12-18 |
| Est. Completion | 2022-07-14 |
| Phase | Phase 2 |
What the finished NCT04615923 record still lists
NCT04615923 is an interventional study that assigns participants to a tested intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (23% higher).
The record links to 0 conditions, and to 2 interventions - of which Matching Placebo is the first listed.
NCT04615923 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04615923 about?
NCT04615923 is a clinical study titled "HEALEY ALS Platform Trial - Regimen D Pridopidine". The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. Regimen D will evaluate the safety and efficacy of a single study drug, pridopidine, in participants with ALS.
What is the current status of trial NCT04615923?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2020-12-18. Estimated completion is 2022-07-14.
What interventions are being tested in trial NCT04615923?
The interventions under investigation include: Matching Placebo (DRUG), Pridopidine (DRUG).
Who is sponsoring clinical trial NCT04615923?
This trial is sponsored by Merit E. Cudkowicz, MD, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04615923's enrollment target sits among peer trials
163 418th of 2000 higher than 1,583 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03180268 · 163 participants · Phase 3
Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery
- NCT04862221 · 163 participants · Phase 2
TReatment for ImmUne Mediated PathopHysiology
- NCT05702229 · 163 participants · Phase 2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
- NCT06137118 · 163 participants · Phase 1
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI